NCT06891183 Percutaneous Thermal Ablation in Lung Tumors
| NCT ID | NCT06891183 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assiut University |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-05-01 |
| Primary Completion | 2026-05-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Lung cancer has a high incidence globally, with Egypt having it as the third most common and most lethal cancer, affecting 16.9% of males and 3.8% of females. While surgery is the preferred treatment for stage 1 non-small cell lung cancer due to positive outcomes, it carries significant risks due to patient comorbidities. Non-invasive treatments like radio frequency ablation (RFA) and microwave ablation (MWA) are alternatives for those unable to undergo surgery. These techniques use energy to destroy tumor tissue with minimal invasiveness and can be guided by computed tomography to ensure accurate ablation.
Eligibility Criteria
Inclusion Criteria: * lung cancer smaller than 5 cm * metastasis to the lung * patients with lung cancer and multiple comorbidities who are unfit for surgery Exclusion Criteria: * lung cancer larger than 5 cm * lung cancer stage II or more * patients who cannot tolerate CT guided needle placement for thermal ablation of lung tumors
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.